Multistate marijuana firm iAnthus Capital reported income of $two.two million for the fourth quarter ended Dec. 31, 2018, up 165% from the similar period a year ago.

For the complete year, iAnthus posted income of $four.five million, up 88% compared with its 2017 fiscal year.

The New York firm reported pro forma income for the quarter – which consists of the financials of not too long ago acquired MPX Bioceutical Corp. – of $14.eight million and $49.three million for the year.

Net loss for the quarter was $15.9 million and $62 million for the complete year, driven respectively by quite a few noncash charges.

The firm has a money balance of $45 million, but iAnthus executives told analysts Tuesday it could get far more than $125 million from warrants currently issued that may perhaps be exercised.

“The quarterly benefits, though certainly uninspiring, are not the true story right here,” Paul Penney, an analyst with Northland Capital Markets, told Marijuana Small business Day-to-day.

“With a strong balance sheet and a extremely capable management group, we totally count on (iAnthus) to effectively execute and open shops effectively.

“This transformation will take the greater aspect of this year and subsequent, but at stabilization, we think (iAnthus) has a sturdy shot at getting one particular of the most respected national cannabis providers.”

With its acquisition of MPX, iAnthus boasts a multistate footprint that consists of operations and licenses in 11 states. Of its 63 offered dispensary licenses, 21 places are operating.

The firm trades on the Canadian Securities Exchange as IAN and on the more than-the-counter exchanges as ITHUF.

Shares of iAnthus stock opened at $7.15 on Tuesday, down from $7.48 a share at close Monday.

(For far more evaluation and in-depth appears at the investment trends and offers driving the cannabis market forward, sign up for our new premium subscription service, Investor Intelligence.)